Company intelligence / Profile preview

Avyxa Pharma

Parsippany, New Jersey, United Statesavyxa.com ↗

Ownership: Private
Development stage: Commercial

Overview

Avyxa Pharma develops and markets complex therapies primarily for cancer patients. At least one small molecule drug has achieved regulatory approval in the European Union since November 1995. The company’s pipeline includes several small molecule candidates targeting various neoplastic diseases as well as select non-oncology indications. Detailed clinical results are not publicly available.

Therapeutic areas: OncologyEndocrinologyImmunologyHematologyNeurologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

4 assets

pemetrexed

Commercial

Indications: Non-small cell lung cancer, Mesothelioma

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Avyxa Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avyxa Pharma.

Explore the full profile